These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 8233719)
21. Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Clandinin MT; Zuberbuhler P; Brown NE; Kielo ES; Goh YK Am J Clin Nutr; 1995 Dec; 62(6):1268-75. PubMed ID: 7491891 [TBL] [Abstract][Full Text] [Related]
22. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. Feingold KR; Soued M; Staprans I; Gavin LA; Donahue ME; Huang BJ; Moser AH; Gulli R; Grunfeld C J Clin Invest; 1989 Apr; 83(4):1116-21. PubMed ID: 2703526 [TBL] [Abstract][Full Text] [Related]
23. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. Maqbool A; Schall JI; Garcia-Espana JF; Zemel BS; Strandvik B; Stallings VA J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):635-44. PubMed ID: 18955866 [TBL] [Abstract][Full Text] [Related]
24. Plasma lipid concentrations in children with cystic fibrosis: the value of a high-fat diet and pancreatic supplementation. Burdge GC; Goodale AJ; Hill CM; Halford PJ; Lambert EJ; Postle AD; Rolles CJ Br J Nutr; 1994 Jun; 71(6):959-64. PubMed ID: 7518243 [TBL] [Abstract][Full Text] [Related]
25. Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis. Schmitt-Grohé S; Hippe V; Igel M; von Bergmann K; Posselt HG; Krahl A; Smaczny C; Wagner TO; Nikolazik W; Schubert R; Lentze MJ; Zielen S Pediatr Res; 2005 Nov; 58(5):903-7. PubMed ID: 16183806 [TBL] [Abstract][Full Text] [Related]
26. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. Gibson RA; Teubner JK; Haines K; Cooper DM; Davidson GP J Pediatr Gastroenterol Nutr; 1986; 5(3):408-15. PubMed ID: 3723260 [TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-alpha inhibits lipid and lipoprotein transport by Caco-2 cells. Mehran M; Seidman E; Marchand R; Gurbindo C; Levy E Am J Physiol; 1995 Dec; 269(6 Pt 1):G953-60. PubMed ID: 8572227 [TBL] [Abstract][Full Text] [Related]
28. Fatty acids in cystic fibrosis in response to a marathon race. Ceder O; Bardón A; Kollberg H; Stanghelle JK; Maehlum S; Skyberg D; Custance J; Dodge J Int J Sports Med; 1988 Feb; 9 Suppl 1():51-5. PubMed ID: 3360545 [TBL] [Abstract][Full Text] [Related]
30. Association of nesfatin-1 and fat mass in cystic fibrosis. Cohen RI; Ginsberg N; Tsang D; Wann LC; Ye X; Liu SF Respiration; 2013; 86(4):312-7. PubMed ID: 23306670 [TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. Feingold KR; Grunfeld C J Clin Invest; 1987 Jul; 80(1):184-90. PubMed ID: 3597772 [TBL] [Abstract][Full Text] [Related]
32. Hypothesis: vitamin E complements polyunsaturated fatty acids in essential fatty acid deficiency in cystic fibrosis. Wood LG; Fitzgerald DA; Garg ML J Am Coll Nutr; 2003 Aug; 22(4):253-7. PubMed ID: 12897038 [TBL] [Abstract][Full Text] [Related]
33. Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Suter S; Schaad UB; Roux-Lombard P; Girardin E; Grau G; Dayer JM Am Rev Respir Dis; 1989 Dec; 140(6):1640-4. PubMed ID: 2604293 [TBL] [Abstract][Full Text] [Related]
34. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Grunfeld C; Kotler DP; Shigenaga JK; Doerrler W; Tierney A; Wang J; Pierson RN; Feingold KR Am J Med; 1991 Feb; 90(2):154-62. PubMed ID: 1996584 [TBL] [Abstract][Full Text] [Related]
35. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis. Brown MA; Morgan WJ; Finley PR; Scuderi P Pediatr Pulmonol; 1991; 10(2):86-91. PubMed ID: 2030926 [TBL] [Abstract][Full Text] [Related]
36. Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. Sezgin N; Sezgin AT; Gullu H; Karabulut A; Barutcu I; Topal E; Yalcintas D; Temel I Tohoku J Exp Med; 2005 Jul; 206(3):219-24. PubMed ID: 15942148 [TBL] [Abstract][Full Text] [Related]
37. Biliary lipid composition in patients with cystic fibrosis. Becker M; Staab D; Leiss O; von Bergmann K J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):308-12. PubMed ID: 2651635 [TBL] [Abstract][Full Text] [Related]
38. Effects of tumor necrosis factor-alpha on peroxidation of plasma lipoprotein lipids in experimental animals and patients. McDonagh J; Fossel ET; Kradin RL; Dubinett SM; Laposata M; Hallaq YA Blood; 1992 Dec; 80(12):3217-26. PubMed ID: 1467525 [TBL] [Abstract][Full Text] [Related]
39. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. Ollero M; Astarita G; Guerrera IC; Sermet-Gaudelus I; Trudel S; Piomelli D; Edelman A J Lipid Res; 2011 May; 52(5):1011-22. PubMed ID: 21335323 [TBL] [Abstract][Full Text] [Related]
40. Relationships between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Thompson GN Eur J Pediatr; 1989 Jan; 148(4):327-9. PubMed ID: 2707278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]